Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pozen MT 100 Indication For Migraine Without Nausea To Be Considered By Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Peripheral & Central Nervous System Drugs Advisory Committee will weigh whether Pozen should go forward with additional study in non-nauseated migraine patients.

You may also be interested in...



Pozen MT 100 Benefit In Migraine Does Not Outweigh Tardive Dyskinesia Risk

FDA's Peripheral & Central Nervous System Drugs Advisory Committee says additional studies of the naproxen/metoclopramide product must show an effect on two-hour pain-free response.

Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly

Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel